Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDE034 · 1 trial · 8 indications
Incidence of dose limiting toxicities; incidence and severity of AEs and SAEs graded based on CTCAE V6.0
Incidence of dose limiting toxicities; incidence and severity of AEs and SAEs graded based on CTCAE V6.0
Objective Response Rate (ORR) per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Part 1:IDE034 Dose Escalation | EXPERIMENTAL | IDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined |
| Part 2: IDE034 Dose Expansion | EXPERIMENTAL | IDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation |
| Name | Type | Description |
|---|---|---|
| IDE034 | DRUG | IDE034 |
Inclusion Criteria: 1. Participant must be at least 18 years of age or the age of maturity per local regulations 2. Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen r...
IDE034 is an investigational small molecule being studied for the treatment of esophageal squamous cell carcinoma. It is also being evaluated in other solid tumor types including high grade serous ovarian cancer, head and neck squamous cell carcinoma, colorectal cancer, castration-resistant prostate cancer, non small cell lung cancer, endometrium cancer, and triple negative breast cancer.
IDE034 targets the proteins B7H3 and PTK7. These are the molecular targets of the investigational drug, which is being developed as a small molecule therapeutic for oncology indications.
IDE034 is being developed by IDEAYA Biosciences, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol IDYA on the stock market.
IDE034 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities and is currently being studied in a Phase 1 clinical trial.
IDE034 is being studied in a Phase 1 clinical trial with the identifier NCT07503808. This trial is recruiting adult participants with locally advanced or metastatic solid tumors, including esophageal squamous cell carcinoma, and is being conducted in the United States.
No, IDE034 is not the same as B7H3 or PTK7. B7H3 and PTK7 are the molecular targets of IDE034, meaning the drug is designed to interact with these proteins. IDE034 is a distinct investigational compound being developed to target these proteins in cancer treatment.